Abstract
Evolution of unresponsiveness to homeostasis-promoting signals from the microenvironment is a hallmark of malignant tumor cells. In Dunning R3327 model rat prostate tumors that are comprised of distinct stromal and epithelial compartments, progression from non-malignant, androgen-responsive tumors to malignancy is characterized by loss of compartmentation coincident with a loss of resident epithelial cell FGFR2IIIb that receives instructive signals from stromal FGF7 and FGF10. Restoration of FGFR2IIIb to malignant tumor cells restores responsiveness to stromal cells, restores distinct stromal and epithelial compartments, and retards malignant progression. Cultured stromal cells from two-compartment tumors are comprised of smooth muscle α-actin-positive cells that express predominantly FGFR3 and fibroblast-like cells devoid of α-actin and FGFR3. Here, we show that it is primarily the smooth muscle cell-like α-actin-expressing stromal cells that survive, morphologically differentiate, and delay tumor incidence and size in the presence of malignant cells in which FGFR2IIIb has been restored. Expression of FGFR3 by transfection in the fibroblast-like stromal cells conferred ability to respond similar to the smooth muscle cell-like stromal cells in which FGFR3 is normally resident. These results highlight the importance of the two-way communication back and forth between stroma and epithelium that is mediated by signaling within the FGFR family during progression to malignancy.
Similar content being viewed by others
References
Aboseif S.; El-Sakka A.; Young P.; Cunha G. Mesenchymal reprogramming of adult human epithelial differentiation. Differentiation 65: 113–118; 1999.
Feng S.; Wang F.; Matsubara A.; Kan M.; McKeehan W. L. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 57: 5369–5378; 1997.
Hayward S. W.; Rosen M. A.; Cunha G. R. Stromal-epithelial interactions in the normal and neoplastic prostate. Br J Urol 79(Suppl 2): 18–26; 1997.
Isaacs J. T.; Heston W. D.; Weissman R. M.; Coffey D. S. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 38: 4353–4359; 1978.
Jin C.; Wang F.; Wu X.; Yu C.; Luo Y.; McKeehan W. L. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res 64: 4555–4562; 2004.
Li Z. G.; Mathew P.; Yang J.; Starbuck M. W.; Zurita A. J.; Liu J.; Sikes C.; Multani A. S.; Efstathiou E.; Lopez A.; Wang J.; Fanning T. V.; Prieto V. G.; Kundra V.; Vazquez E. S.; Troncoso P.; Raymond A. K.; Logothetis C. J.; Lin S. H.; Maity S.; Navone N. M. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Investig 118: 2697–2710; 2008.
Lu W.; Luo Y.; Kan M.; McKeehan W. L. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 274: 12827–12834; 1999.
Matsubara A.; Kan M.; Feng S.; McKeehan W. L. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 58: 1509–1514; 1998.
Memarzadeh S.; Xin L.; Mulholland D. J.; Mansukhani A.; Wu H.; Teitell M. A.; Witte O. N. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12: 572–585; 2007.
Wu X.; Jin C.; Wang F.; Yu C.; McKeehan W. L. Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors. Cancer Res 63: 4936–4944; 2003.
Yan G.; Fukabori Y.; McBride G.; Nikolaropolous S.; McKeehan W. L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13: 4513–4522; 1993.
Yan G.; Fukabori Y.; Nikolaropoulos S.; Wang F.; McKeehan W. L. Heparin-binding keratinocyte growth factor is a candidate stromal-to- epithelial-cell andromedin. Mol Endocrinol (Baltimore, Md 6: 2123–2128; 1992.
Acknowledgments
This work was supported by Public Health Service grant P50CA140388 (FW/WLM), the Susan Komen Foundation (WLM), and aid from the John S. Dunn Research Foundation (WLM).
Author information
Authors and Affiliations
Corresponding author
Additional information
Editor: T. Okamoto
Rights and permissions
About this article
Cite this article
Jin, C., Yang, C., Wu, X. et al. FGFR3-expressing smooth muscle-like stromal cells differentiate in response to FGFR2IIIb-expressing prostate tumor cells and delay tumor progression. In Vitro Cell.Dev.Biol.-Animal 47, 500–505 (2011). https://doi.org/10.1007/s11626-011-9432-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11626-011-9432-5